We represent branded and generic pharmaceutical clients in ANDA litigation under the Hatch-Waxman framework, handling Paragraph IV challenges, exclusivity disputes, and regulatory strategy. Our team coordinates scientific, regulatory, and legal analysis to manage stay motions, claim construction, and damages exposure. We aim to resolve disputes efficiently while safeguarding market entry timing and product value.
We represent branded and generic pharmaceutical clients in ANDA litigation under the Hatch-Waxman framework, handling Paragraph IV challenges, exclusivity disputes, and regulatory strategy. Our team coordinates scientific, regulatory, and legal analysis to manage stay motions, claim construction, and damages exposure. We aim to resolve disputes efficiently while safeguarding market entry timing and product value.